Valuation: BriaCell Therapeutics Corp.

Market Cap 31.07M 27.34M 25.41M 23.33M 43.79M 3B 44.52M 302M 118M 1.47B 117M 114M 5.09B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 13.21M 11.62M 10.8M 9.92M 18.61M 1.28B 18.92M 128M 50.09M 625M 49.58M 48.51M 2.16B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-3.76%
1 week-4.02%
Current month+10.49%
1 month+18.15%
3 months-7.73%
6 months-17.70%
Current year-49.65%
1 week 3.5
Extreme 3.5
3.91
1 month 2.94
Extreme 2.945
4
Current year 2.6
Extreme 2.6
12.1
1 year 2.6
Extreme 2.6
14.68
3 years 2.6
Extreme 2.6
1,138.5
5 years 2.6
Extreme 2.6
1,870.5
10 years 2.6
Extreme 2.6
8,424.08
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 63 2016-05-09
Director/Board Member 74 2019-03-06
Director/Board Member 68 2019-03-17
Change 5-day change 1-year change 3-year change Capi.($)
-3.76%-4.02% - - 31.07M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.31%+1.28%+40.62%+170.95% 26.68B
Weighted average by Cap. -0.87%+2.10%+41.18%+135.69%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.22M -3.92M -3.6M -6.75M -463M -6.87M -46.53M -18.17M -227M -17.99M -17.6M -785M -26.31M -23.15M -21.52M -19.76M -37.08M -2.54B -37.7M -256M -99.79M -1.25B -98.77M -96.64M -4.31B
Net Debt -862K -759K -705K -647K -1.21M -83.24M -1.24M -8.37M -3.27M -40.8M -3.24M -3.17M -141M -17.87M -15.72M -14.61M -13.41M -25.18M -1.73B -25.6M -174M -67.76M -846M -67.07M -65.62M -2.93B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-07-24 $3.580 -3.76% 63,940
26-07-23 $3.720 +3.33% 36,937
26-07-22 $3.600 -4.00% 60,998
26-07-21 $3.750 +2.88% 40,324
26-07-20 $3.645 -2.28% 97,197

Quarterly revenue - Rate of surprise